97 related articles for article (PubMed ID: 17496005)
21. Intravenous furosemide injection during 18F-FDG PET acquisition.
López-Gandul S; Pérez-Moure G; García-Garzón JR; Soler-Peter M; Simó-Perdigó M; Lomeña F
J Nucl Med Technol; 2006 Dec; 34(4):228-31. PubMed ID: 17146112
[TBL] [Abstract][Full Text] [Related]
22. Comparison of early and delayed FDG PET for evaluation of biliary stricture.
Nishiyama Y; Yamamoto Y; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Ohkawa M
Nucl Med Commun; 2007 Dec; 28(12):914-9. PubMed ID: 18090217
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
24. Low-dose oral propranolol could reduce brown adipose tissue F-18 FDG uptake in patients undergoing PET scans.
Parysow O; Mollerach AM; Jager V; Racioppi S; San Roman J; Gerbaudo VH
Clin Nucl Med; 2007 May; 32(5):351-7. PubMed ID: 17452860
[TBL] [Abstract][Full Text] [Related]
25. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
26. Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT.
Beyer T; Antoch G; Bockisch A; Stattaus J
J Nucl Med; 2005 Mar; 46(3):429-35. PubMed ID: 15750155
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
Spence AM; Muzi M; Mankoff DA; O'Sullivan SF; Link JM; Lewellen TK; Lewellen B; Pham P; Minoshima S; Swanson K; Krohn KA
J Nucl Med; 2004 Oct; 45(10):1653-9. PubMed ID: 15471829
[TBL] [Abstract][Full Text] [Related]
28. Source of impaired image quality in 3D whole-body FDG PET scanning.
Paans AM; Boerdijk SM; Willemsen AT; Pruim J
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1207; author reply 1208. PubMed ID: 15197498
[No Abstract] [Full Text] [Related]
29. Optimizing experimental protocols for quantitative behavioral imaging with 18F-FDG in rodents.
Schiffer WK; Mirrione MM; Dewey SL
J Nucl Med; 2007 Feb; 48(2):277-87. PubMed ID: 17268026
[TBL] [Abstract][Full Text] [Related]
30. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
[TBL] [Abstract][Full Text] [Related]
31. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of mouse tail-vein injections both qualitatively and quantitatively on small-animal PET tail scans.
Vines DC; Green DE; Kudo G; Keller H
J Nucl Med Technol; 2011 Dec; 39(4):264-70. PubMed ID: 21969354
[TBL] [Abstract][Full Text] [Related]
33. Optimization of the reference region method for dual pharmacokinetic modeling using Gd-DTPA/MRI and (18) F-FDG/PET.
Poulin É; Lebel R; Croteau É; Blanchette M; Tremblay L; Lecomte R; Bentourkia M; Lepage M
Magn Reson Med; 2015 Feb; 73(2):740-8. PubMed ID: 24604379
[TBL] [Abstract][Full Text] [Related]
34. What is the most appropriate scan timing for intraoperative detection of malignancy using 18F-FDG-sensitive gamma probe? Preliminary phantom and preoperative patient study.
Higashi T; Saga T; Ishimori T; Mamede M; Ishizu K; Fujita T; Mukai T; Sato S; Kato H; Yamaoka Y; Matsumoto K; Senda M; Konishi J
Ann Nucl Med; 2004 Apr; 18(2):105-14. PubMed ID: 15195757
[TBL] [Abstract][Full Text] [Related]
35. Human Radiation Dosimetry for Orally and Intravenously Administered
Srinivasan S; Crandall JP; Gajwani P; Sgouros G; Mena E; Lodge MA; Wahl RL
J Nucl Med; 2020 Apr; 61(4):613-619. PubMed ID: 31628217
[TBL] [Abstract][Full Text] [Related]
36. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
Zhuang H; Pourdehnad M; Lambright ES; Yamamoto AJ; Lanuti M; Li P; Mozley PD; Rossman MD; Albelda SM; Alavi A
J Nucl Med; 2001 Sep; 42(9):1412-7. PubMed ID: 11535734
[TBL] [Abstract][Full Text] [Related]
37. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
Saif MW; Cornfeld D; Modarresifar H; Ojha B
J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
[TBL] [Abstract][Full Text] [Related]
38. Anterior layering of excreted 18F-FDG in the bladder on PET/CT: frequency and cause.
Purcell DD; Coakley FV; Franc BL; Hawkins RA; Boddington SE; Yeh BM
AJR Am J Roentgenol; 2007 Aug; 189(2):W96-9. PubMed ID: 17646448
[TBL] [Abstract][Full Text] [Related]
39. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
40. Oral administration of F-18 FDG to evaluate a single pulmonary nodule by positron emission tomography in a patient with poor intravenous access.
Franc B; Carlisle MR; Segall G
Clin Nucl Med; 2003 Jul; 28(7):541-4. PubMed ID: 12819404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
